Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Emerging Roles of Lysyl Oxidases in the Cardiovascular System, New Concepts and Therapeutic Challenges

  • Martínez-González, José|||0000-0002-3894-7166
  • Varona, Saray|||0000-0002-7375-313X
  • Cañes Esteve, Laia|||0000-0002-9579-1321
  • Galán, María|||0000-0002-4758-8388
  • Briones, Ana|||0000-0001-8218-5579
  • Cachofeiro, Victoria
  • Rodríguez, Cristina|||0000-0002-6472-5647
Lysyl oxidases (LOX and LOX-likes (LOXLs) isoenzymes) belong to a family of copper-dependent enzymes classically involved in the covalent cross-linking of collagen and elastin, a pivotal process that ensures extracellular matrix (ECM) stability and provides the tensile and elastic characteristics of connective tissues. Besides this structural role, in the last years, novel biological properties have been attributed to these enzymes, which can critically influence cardiovascular function. LOX and LOXLs control cell proliferation, migration, adhesion, differentiation, oxidative stress, and transcriptional regulation and, thereby, their dysregulation has been linked to a myriad of cardiovascular pathologies. Lysyl oxidase could modulate virtually all stages of the atherosclerotic process, from endothelial dysfunction and plaque progression to calcification and rupture of advanced and complicated plaques, and contributes to vascular stiffness in hypertension. The alteration of LOX/LOXLs expression underlies the development of other vascular pathologies characterized by a destructive remodeling of the ECM, such as aneurysm and artery dissections, and contributes to the adverse myocardial remodeling and dysfunction in hypertension, myocardial infarction, and obesity. This review examines the most recent advances in the study of LOX and LOXLs biology and their pathophysiological role in cardiovascular diseases with special emphasis on their potential as therapeutic targets.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nr4a3, A key nuclear receptor in vascular biology, cardiovascular remodeling and beyond

  • Martínez-González, José|||0000-0002-3894-7166
  • Cañes Esteve, Laia|||0000-0002-9579-1321
  • Alonso Nieto, Judith|||0000-0003-0537-0417
  • Ballester-Servera, Carme|||0000-0001-7858-3064
  • Rodríguez Sinovas, Antonio|||0000-0003-2930-8773
  • Corrales Insa, Irene|||0000-0002-0647-0340
  • Rodríguez, Cristina|||0000-0002-6472-5647
The mechanisms committed in the activation and response of vascular and inflammatory immune cells play a major role in tissue remodeling in cardiovascular diseases (CVDs) such as atherosclerosis, pulmonary arterial hypertension, and abdominal aortic aneurysm. Cardiovascular remodeling entails interrelated cellular processes (proliferation, survival/apoptosis, inflammation, extracellular matrix (ECM) synthesis/degradation, redox homeostasis, etc.) coordinately regulated by a reduced number of transcription factors. Nuclear receptors of the subfamily 4 group A (NR4A) have recently emerged as key master genes in multiple cellular processes and vital functions of different organs, and have been involved in a variety of high-incidence human pathologies including atherosclerosis and other CVDs. This paper reviews the major findings involving NR4A3 (Neuron-derived Orphan Receptor 1, NOR-1) in the cardiovascular remodeling operating in these diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rolipram prevents the formation of abdominal aortic aneurysm (Aaa) in mice, pde4b as a target in AAA

  • Varona, Saray|||0000-0002-7375-313X
  • Puertas Umbert, Lídia|||0000-0002-2739-6522
  • Galán, María|||0000-0002-4758-8388
  • Orriols, Mar
  • Cañes Esteve, Laia|||0000-0002-9579-1321
  • Aguiló, Silvia|||0000-0003-0672-8388
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Sirvent, M.
  • Andrés, Vicente|||0000-0002-0125-7209
  • Martínez-González, José|||0000-0002-3894-7166
  • Rodríguez, Cristina|||0000-0002-6472-5647
Abdominal aortic aneurysm (AAA) is a common life-threatening condition characterized by exacerbated inflammation and the generation of reactive oxygen species. Pharmacological treatments to slow AAA progression or to prevent its rupture remain a challenge. Targeting phosphodiesterase 4 (PDE4) has been verified as an effective therapeutic strategy for an array of inflammatory conditions; however, no studies have assessed yet PDE4 in AAA. Here, we used angiotensin II (AngII)-infused apolipoprotein E deficient mice to study the involvement of the PDE4 subfamily in aneurysmal disease. PDE4B but not PDE4D was upregulated in inflammatory cells from both experimental and human AAA. The administration of the PDE4 selective inhibitor rolipram (3 mg/kg/day) to AngII-challenged mice (1000 ng/kg bodyweight/min) protected against AAA formation, limiting the progressive increase in the aortic diameter without affecting the blood pressure. The drug strongly attenuated the rise in vascular oxidative stress (superoxide anion) induced by AngII, and decreased the expression of inflammatory markers, as well as the recruitment of macrophages (MAC3+), lymphocytes (CD3+), and neutrophils (ELANE+) into the vessel wall. Rolipram also normalized the vascular MMP2 expression and MMP activity, preserving the elastin integrity and improving the vascular remodelling. These results point to PDE4B as a new therapeutic target for AAA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CD69-oxLDL ligand engagement induces Programmed Cell Death 1 (PD-1) expression in human CD4 + T lymphocytes

  • Jiménez-Fernández, María
  • Rodríguez, Cristina|||0000-0002-6472-5647
  • Cañes Esteve, Laia|||0000-0002-9579-1321
  • Ballester-Servera, Carme|||0000-0001-7858-3064
  • Vara, Alicia
  • Requena, Silvia
  • Fuente, Hortensia de la
  • Martínez-González, José|||0000-0002-3894-7166
  • Sánchez-Madrid, Francisco|||0000-0001-5303-0762
The mechanisms that control the inflammatory-immune response play a key role in tissue remodelling in cardiovascular diseases. T cell activation receptor CD69 binds to oxidized low-density lipoprotein (oxLDL), inducing the expression of anti-inflammatory NR4A nuclear receptors and modulating inflammation in atherosclerosis. To understand the downstream T cell responses triggered by the CD69-oxLDL binding, we incubated CD69-expressing Jurkat T cells with oxLDL. RNA sequencing revealed a differential gene expression profile dependent on the presence of CD69 and the degree of LDL oxidation. CD69-oxLDL binding induced the expression of NR4A receptors (NR4A1 and NR4A3), but also of PD-1. These results were confirmed using oxLDL and a monoclonal antibody against CD69 in CD69-expressing Jurkat and primary CD4 + lymphocytes. CD69-mediated induction of PD-1 and NR4A3 was dependent on NFAT activation. Silencing NR4A3 slightly increased PD-1 levels, suggesting a potential regulation of PD-1 by this receptor. Moreover, expression of PD-1, CD69 and NR4A3 was increased in human arteries with chronic inflammation compared to healthy controls, with a strong correlation between PD-1 and CD69 mRNA expression (r = 0.655 P < 0.0001). Moreover, PD-1 was expressed in areas enriched in CD3 infiltrating T cells. Our results underscore a novel mechanism of PD-1 induction independent of TCR signalling that might contribute to the role of CD69 in the modulation of inflammation and vascular remodelling in cardiovascular diseases.